USA flag logo/image

An Official Website of the United States Government

In Vitro Assay to Assess Chemical Toxicity in Retinal Primary Cell Cultures

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85626
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
ES015667
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ACUCELA, INC.
ACUCELA INC. 21720 23rd Dr. SE Bothell, WA 98021
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: In Vitro Assay to Assess Chemical Toxicity in Retinal Primary Cell Cultures
Agency: HHS
Contract: 1R43ES015667-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The average person in the U.S. contains detectable levels of more than 100 industrial compounds, pollutants, and chemicals, but predicting the relative risk of this exposure, especially over time, is challenging (US CDC , 2003). Successful development and commercialization of next-generation, low-cost, high-performance technology for predicting compound toxicity would help assess safe levels of environmental exposure-thereby reducing national healthcare costs and producin g safer working/living environments. This exposure to environmental toxins plays an important role in aging and oxidation processes, which are key risk factors of macular degeneration, a process that eventually leads to blindness. Importantly, however, the re are currently no accepted or practical tests for measuring the retinal toxicity of compounds directly. In vivo assessments of retinal toxicity, when performed, require large numbers of animals, are time-consuming and expensive, and do not provide data o n toxicity progression. The ability to prepare stable primary mixed retinal cultures in vitro would allow screening and prioritization of further toxicity testing in a rapid and cost-effective manner. Ideally, such a system should allow differentiation of light-dependent toxicity [phototoxicity] and general toxic effects, and would mimic in vivo toxicity. Therefore, the overall goal of this multi-phase SBIR project is to develop, validate, and commercialize Ocuscreen(tm), Acucela's proprietary retinal cultu re screening system, as a next-generation in vitro system for ranking the relative (photo)toxicity of environmental toxins, and to have this assay incorporated as a part of the regulatory framework for the commercialization of chemicals. The Specific Aims for Phase I of this project are to identify a group of known retinal toxicants, to prove the feasibility of ranking their (photo)toxic potential, and finally to show these rankings correlate with in vivo literature data. Demonstrating that we can predict ( photo)toxicity (or lack thereof) in a small class of representative compounds will establish the predictive potential of our new system within the limited scope of the Phase I proof-of-concept project, and will set the stage for a larger Phase II demonstra tion effort. Phase I will also provide sufficient data for Ocuscreen to be nominated as an alternative test method to the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and will allow us to determine how well Ocuscree n meets ICCVAM performance standards. Phase II work will involve establishing a large photoreceptor toxicity database of chemicals-built both from existing knowledge and results from our assay system-to improve the predictive accuracy of compound safety. P hase III of the project will be focused on establishing a commercial screening service for photoreceptor toxicity. Even without formal regulatory adoption, the ability to accurately predict toxic potential will provide a compelling service to chemical comp anies and will represent an important step in protecting human health. The average person in the U.S. contains detectable levels of more than 100 industrial compounds, pollutants, and chemicals, but predicting the risk of this exposure, especially to eye t oxicity, is challenging. Current prediction methods require large numbers of animals, are time-consuming and expensive, and do not provide data on toxicity progression. The overall goal of this project is to develop, validate, and commercialize Acucela's p roprietary retinal culture screening system as a next-generation, practical in vitro system for evaluating the health effects of environmental toxicants.

Principal Investigator:

Raymond D. Price
2068535774
RAYMOND.PRICE@ACUCELA.COM

Business Contact:

Jeff Chen
sayuri@acucela.com
Small Business Information at Submission:

ACUCELA, INC.
ACUCELA INC. 21720 23rd Dr. SE Bothell, WA 98021

EIN/Tax ID: 102059261
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No